清热解毒中药对肝癌患者血清CXCL1的影响
|
摘要
目的:观察清热解毒中药对原发性肝癌患者血清CXCL1 mRNA和蛋白表达的影响。方法:60例受试者分为正常对照组(健康者24例)和肝癌组(原发性肝癌患者36例),比较两组受试者血清CXCL1 mRNA和蛋白表达情况。同时肝癌组随机分为两组:服用清热解毒中药组(19例)和未服用清热解毒中药组(17例),比较两组患者血清CXCL1 mRNA和蛋白表达情况。正常对照组与肝癌组均抽血送检,其中肝癌组中的中药组服用清热解毒中药方;通过RT-PCR、Western检测血清CXCL1的mRNA和蛋白表达,比较正常对照组与肝癌组之间的差异,进一步比较服用清热解毒中药组与未服用清热解毒中药组之间的差异,探讨清热解毒中药对CXCL1 mRNA和蛋白水平的影响。结果:①正常对照组、肝癌组两组血清CXCL1 mRNA水平比较,差异有统计学意义(P<0.01),正常对照组显著低于肝癌组;服用清热解毒中药组与未服用清热解毒中药组比较,CXCL1 mRNA水平差异有统计学意义(P<0.01),服用清热解毒中药组显著低于未服用清热解毒中药组。②正常对照组、肝癌组两组血清CXCL1蛋白水平比较,差异有统计学意义(P<0.01),正常对照组显著低于肝癌组(P<0.01);服用清热解毒中药组与未服用清热解毒中药组CXCL1蛋白水平比较,差异有统计学意义(P<0.01),服用清热解毒中药组显著低于未服用清热解毒中药组。结论:原发性肝癌患者血清CXCL1的mRNA、蛋白水平高于健康人的表达,清热解毒中药方可以显著下调肝癌患者血清中CXCL1的mRNA含量和蛋白的表达。
Objective:To observe the effect of Chinese medicine with heat-clearing and toxin-resolving function on serum CXCL1 mRNA and protein expression in patients with primary liver cancer.Methods:60 cases were divided into normal control group(24 healthy cases) and liver cancer group(36 cases of primary liver cancer patients).The serum CXCL1 mRNA and protein expression were compared between the two groups.At the same time,the liver cancer group was randomly divided into two groups:the group taking Chinese medicine with heat-clearing and toxin-resolving function(19 cases) and the group not taking Chinese medicine with heat-clearing and toxin-resolving function(17 cases).The serum CXCL1 mRNA and protein expression were compared between the two groups.Both the normal control group and the liver cancer group were given blood for examination,and the Chinese medicine group in the liver cancer group was given Chinese medicine prescription with heat-clearing and toxin-resolving function.The mRNA and protein content of serum CXCL1 were detected by RT-PCR and Western methods,and the difference between normal control group and liver cancer group was compared.To further compare the differences between the group taking Chinese medicine with heat-clearing and toxin-resolving function and the group not taking Chinese medicine with heat-clearing and toxin-resolving function,and to explore the effect of Qingrejiedu Chinese medicine on CXCL1 mRNA and protein levels.Results:①The serum CXCL1 mRNA levels in the normal control group and the liver cancer group were significantly different(P<0.01),and the normal control group was significantly lower than the liver cancer group.The difference of CXCL1 mRNA level between the group taking Chinese medicine with heat-clearing and toxin-resolving function and the group not taking Chinese medicine with heat-clearing and toxin-resolving function was statistically significant(P<0.01).The group taking Chinese medicine with heat-clearing and toxin-resolving function was significantly lower than the group not taking Chinese medicine with heat-clearing and toxin-resolving function.②There were significant differences in serum CXCL1 protein levels between the normal control group and the liver cancer group(P<0.01),and the normal control group was significantly lower than the liver cancer group(P<0.01).The difference of CXCL1 protein level between the group taking Chinese medicine with heat-clearing and toxin-resolving function and the group not taking Chinese medicine with heat-clearing and toxin-resolving function was statistically significant(P<0.01).The group taking Chinese medicine with heat-clearing and toxin-resolving function was significantly lower than the group not taking Chinese medicine with heat-clearing and toxin-resolving function.Conclusion:The mRNA and protein levels of serum CXCL1 in patients with primary liver cancer are higher than those in healthy people.Chinese medicine with heat-clearing and toxin-resolving function can significantly down-regulate the mRNA and protein expression of CXCL1 in serum of patients with liver cancer.
Objective:To observe the effect of Chinese medicine with heat-clearing and toxin-resolving function on serum CXCL1 mRNA and protein expression in patients with primary liver cancer.Methods:60 cases were divided into normal control group(24 healthy cases) and liver cancer group(36 cases of primary liver cancer patients).The serum CXCL1 mRNA and protein expression were compared between the two groups.At the same time,the liver cancer group was randomly divided into two groups:the group taking Chinese medicine with heat-clearing and toxin-resolving function(19 cases) and the group not taking Chinese medicine with heat-clearing and toxin-resolving function(17 cases).The serum CXCL1 mRNA and protein expression were compared between the two groups.Both the normal control group and the liver cancer group were given blood for examination,and the Chinese medicine group in the liver cancer group was given Chinese medicine prescription with heat-clearing and toxin-resolving function.The mRNA and protein content of serum CXCL1 were detected by RT-PCR and Western methods,and the difference between normal control group and liver cancer group was compared.To further compare the differences between the group taking Chinese medicine with heat-clearing and toxin-resolving function and the group not taking Chinese medicine with heat-clearing and toxin-resolving function,and to explore the effect of Qingrejiedu Chinese medicine on CXCL1 mRNA and protein levels.Results:①The serum CXCL1 mRNA levels in the normal control group and the liver cancer group were significantly different(P<0.01),and the normal control group was significantly lower than the liver cancer group.The difference of CXCL1 mRNA level between the group taking Chinese medicine with heat-clearing and toxin-resolving function and the group not taking Chinese medicine with heat-clearing and toxin-resolving function was statistically significant(P<0.01).The group taking Chinese medicine with heat-clearing and toxin-resolving function was significantly lower than the group not taking Chinese medicine with heat-clearing and toxin-resolving function.②There were significant differences in serum CXCL1 protein levels between the normal control group and the liver cancer group(P<0.01),and the normal control group was significantly lower than the liver cancer group(P<0.01).The difference of CXCL1 protein level between the group taking Chinese medicine with heat-clearing and toxin-resolving function and the group not taking Chinese medicine with heat-clearing and toxin-resolving function was statistically significant(P<0.01).The group taking Chinese medicine with heat-clearing and toxin-resolving function was significantly lower than the group not taking Chinese medicine with heat-clearing and toxin-resolving function.Conclusion:The mRNA and protein levels of serum CXCL1 in patients with primary liver cancer are higher than those in healthy people.Chinese medicine with heat-clearing and toxin-resolving function can significantly down-regulate the mRNA and protein expression of CXCL1 in serum of patients with liver cancer.
引文
[1]PARKIN D M,BRAY F,FERLAY J,et al.Global cancer statistics[J].CA Cancer J Clin,2005,55(1):74-108.
[2]CHEN X,LIU HP,LI M,et al.Advances in non-surgical management of primary liver cancer[J].World J Gastroenterol,2014,20(44):16630-16638.
[3]JEMAL A,BRAY F,CENTER MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(1):69-90.
[4]异常凝血酶原(DCP)可用于肝癌早期诊断[J].临床检验杂志,2013,31(6):414-414.
[5]巨大维,魏品康.清热解毒中药在恶性肿瘤防治中的药用机理与应用[J].吉林中医药,2007,27(1):60-62.
[6]潘敏求,潘博.健脾理气、化瘀软坚、清热解毒法治疗原发性肝癌的体会[J].湖南中医杂志,2009,25(6):21-22.
[7]韩克起,谢国群.中药联合肝动脉栓塞化疗术治疗中晚期肝癌临床疗效观察[J].中国中西医结合消化杂志,2013,21(1):492-495.
[8]钱朱萍,谢国群,郭晓冬,等.清热解毒方联合西医常规疗法防治中晚期原发性肝癌经导管动脉化疗栓塞术后综合征的临床研究[J].上海中医药杂志,2012,46(2):35-37.
[9]VANDERCAPPELLEN J,VAN DAMME J,STRUYF S,et al.The role of CXC chemokines and their receptors in cancer[J].Cancer Lett,2008,267(2):226-244.
[10]RAJENDRA K,SINGH A S.Role of Chemokines and Chemokine Receptors in Prostate Cancer Development and Progression[J].J Cancer Sci Ther,2010,2(4):89-94.
[11]PINTO S,MARTíNEZ-ROMERO A,O′CONNOR JE,et al.Intracellular coexpression of CXC-and CC-chemokine receptors and their ligands in human melanoma cell lines and dynamic variations after xenotransplantation[J].BMC Cancer,2014,14(1):118.
[12]XU XJ,YANG BW,GONG FX,et al.Expression and role of CXC chemokine 5 in liver cancer cells.[J].Zhonghua Yi Xue Za Zhi,2012,92(38):2716-2719.
[13]HOU KZ,FU ZQ,GONG H,et al.Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition.[J].World J Gastroenterol,2015,21(2):475-483.
[14]SHI JY,YANG LX,WANG ZC,et al.CC chemokine receptor-like 1 functions as a tumour suppressor by impairing CCR7-related chemotaxis in hepatocellular carcinoma[J].J Pathol,2015,235(4):546-558.
[15]CAO Z,FU B,DENG B,et al.Over expression of Chemokine(C-X-C) ligand 1(CXCL1) associated with tumor progression and poor prognosis in hepatocellular carcinoma.[J].Cancer Cell Int,2014,14(1):86.
[16]郑国银,凌昌全.中医药防治肝癌机制研究进展[J].肿瘤,2008,28(9):813-817.
[17]徐敬宣,薛娇,钱晓萍,等.石见穿的化学成分及抗肿瘤作用研究进展[J].现代肿瘤医学,2011,19(3),587-589.
[18]谢宗万.《本草纲目拾遗》石打穿与石见穿的品种考证[J].中国实验方剂学杂志,2001,25(1):49-51.
[19]柴瑞震.抗癌平丸治疗消化系统肿瘤药理实验与临床研究[J].中医药学刊,2003,21(12):1999-2001.
[20]万旭英,张亚妮,张晨,等.猫人参注射液体外抗肝癌实验研究[J].浙江中医学院学报,2004,28(2):45-47.
[21]GORBACHEV A V,FAIRCHILD R L.Regulation of chemokine expression in the tumor microenvironment[J].Crit Rev Immunol,2014,34(2):103-120.
[22]BANDAPALLI OR,EHRMANN F,EHEMANN V,et al.Down-regulation of CXCL1 inhibits tumor growth in colorectal liver metastasis[J].Cytokine,2012,57(1):46-53.
[23]TANG KH,MA S,LEE TK,et al.CD133(+) liver tumor-initiating cells promote tumor angiogenesis,growth,and self-renewal through neurotensin/interleukin-8/CXCL1 signaling[J].Hepatology,2012,55(3):807-820.
[2]CHEN X,LIU HP,LI M,et al.Advances in non-surgical management of primary liver cancer[J].World J Gastroenterol,2014,20(44):16630-16638.
[3]JEMAL A,BRAY F,CENTER MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(1):69-90.
[4]异常凝血酶原(DCP)可用于肝癌早期诊断[J].临床检验杂志,2013,31(6):414-414.
[5]巨大维,魏品康.清热解毒中药在恶性肿瘤防治中的药用机理与应用[J].吉林中医药,2007,27(1):60-62.
[6]潘敏求,潘博.健脾理气、化瘀软坚、清热解毒法治疗原发性肝癌的体会[J].湖南中医杂志,2009,25(6):21-22.
[7]韩克起,谢国群.中药联合肝动脉栓塞化疗术治疗中晚期肝癌临床疗效观察[J].中国中西医结合消化杂志,2013,21(1):492-495.
[8]钱朱萍,谢国群,郭晓冬,等.清热解毒方联合西医常规疗法防治中晚期原发性肝癌经导管动脉化疗栓塞术后综合征的临床研究[J].上海中医药杂志,2012,46(2):35-37.
[9]VANDERCAPPELLEN J,VAN DAMME J,STRUYF S,et al.The role of CXC chemokines and their receptors in cancer[J].Cancer Lett,2008,267(2):226-244.
[10]RAJENDRA K,SINGH A S.Role of Chemokines and Chemokine Receptors in Prostate Cancer Development and Progression[J].J Cancer Sci Ther,2010,2(4):89-94.
[11]PINTO S,MARTíNEZ-ROMERO A,O′CONNOR JE,et al.Intracellular coexpression of CXC-and CC-chemokine receptors and their ligands in human melanoma cell lines and dynamic variations after xenotransplantation[J].BMC Cancer,2014,14(1):118.
[12]XU XJ,YANG BW,GONG FX,et al.Expression and role of CXC chemokine 5 in liver cancer cells.[J].Zhonghua Yi Xue Za Zhi,2012,92(38):2716-2719.
[13]HOU KZ,FU ZQ,GONG H,et al.Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition.[J].World J Gastroenterol,2015,21(2):475-483.
[14]SHI JY,YANG LX,WANG ZC,et al.CC chemokine receptor-like 1 functions as a tumour suppressor by impairing CCR7-related chemotaxis in hepatocellular carcinoma[J].J Pathol,2015,235(4):546-558.
[15]CAO Z,FU B,DENG B,et al.Over expression of Chemokine(C-X-C) ligand 1(CXCL1) associated with tumor progression and poor prognosis in hepatocellular carcinoma.[J].Cancer Cell Int,2014,14(1):86.
[16]郑国银,凌昌全.中医药防治肝癌机制研究进展[J].肿瘤,2008,28(9):813-817.
[17]徐敬宣,薛娇,钱晓萍,等.石见穿的化学成分及抗肿瘤作用研究进展[J].现代肿瘤医学,2011,19(3),587-589.
[18]谢宗万.《本草纲目拾遗》石打穿与石见穿的品种考证[J].中国实验方剂学杂志,2001,25(1):49-51.
[19]柴瑞震.抗癌平丸治疗消化系统肿瘤药理实验与临床研究[J].中医药学刊,2003,21(12):1999-2001.
[20]万旭英,张亚妮,张晨,等.猫人参注射液体外抗肝癌实验研究[J].浙江中医学院学报,2004,28(2):45-47.
[21]GORBACHEV A V,FAIRCHILD R L.Regulation of chemokine expression in the tumor microenvironment[J].Crit Rev Immunol,2014,34(2):103-120.
[22]BANDAPALLI OR,EHRMANN F,EHEMANN V,et al.Down-regulation of CXCL1 inhibits tumor growth in colorectal liver metastasis[J].Cytokine,2012,57(1):46-53.
[23]TANG KH,MA S,LEE TK,et al.CD133(+) liver tumor-initiating cells promote tumor angiogenesis,growth,and self-renewal through neurotensin/interleukin-8/CXCL1 signaling[J].Hepatology,2012,55(3):807-820.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |